Rosario, Argentina Clinical Trials

A listing of Rosario, Argentina clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 137 clinical trials
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With sJIA

The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA).

Instituto Centralizado de Asistencia e Investigacion Clinica
 (1.2 away) Contact site
  • 0 views
  • 16 Jul, 2021
  • +119 other locations
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

This study will evaluate the efficacy and safety of pembrolizumab (MK-3475) with lenvatinib (E7080/MK-7902) vs. docetaxel in participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with one prior anti-PD-1/PD-L1 monoclonal antibody (mAb). The primary hypotheses of this study are that …

pd-l1
pembrolizumab
monoclonal antibodies
progressive disease
mk-3475
Sanatorio Parque ( Site 2005)
 (2.6 away) Contact site
  • 122 views
  • 01 Aug, 2021
  • +149 other locations
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia

The purpose of this study is to compare the efficacy and safety of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated Staphylococcus aureus bacteremia.

British Sanatorium SA
 (2.6 away) Contact site
  • 45 views
  • 14 Jul, 2021
  • +125 other locations
A Safety Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA

A randomized withdrawal study in which responders to open-label treatment with tofacitinib will be randomized in a 1:1 ratio to tofacitinib or placebo in a double-blind phase. In the double-blind phase "time to sJIA flare" will be evaluated as primary endpoint and subjects will be discontinued once they experience sJIA …

Hospital Britanico de Buenos Aires
 (172.9 away) Contact site
  • 134 views
  • 02 Aug, 2021
  • +100 other locations
LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active Non-Infectious Uveitis of the Posterior Segment of the Eye

This is a Phase III study to assess the efficacy and safety of DE-109 440 g every 2 months in subjects with active, non-infectious uveitis of the posterior segment of the eye (NIU-PS). There is a 6-month, single-arm, open-label period after completion of the 6-month doublemasked, controlled period allows the …

Oftalmologia Global
 (2.6 away) Contact site
  • 126 views
  • 01 Aug, 2021
  • +89 other locations
Long-term Safety Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study. Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody …

ofatumumab
tetanus
pneumococcal conjugate vaccine
Novartis Investigative Site
 (2.6 away) Contact site
  • 234 views
  • 16 May, 2021
  • +260 other locations
Pembrolizumab Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

This is a randomized, double-blind, study that compares pembrolizumab with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy. The primary hypothesis is that pembrolizumab is superior to placebo in increasing …

adjuvant therapy
pembrolizumab
mk-3475
cancer
Centro Oncol gico de Rosario ( Site 0003)
 (2.6 away) Contact site
  • 69 views
  • 03 Aug, 2021
  • +146 other locations
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer

Novartis Investigative Site
 (2.6 away) Contact site
  • 214 views
  • 17 Jul, 2021
  • +362 other locations
SAR408701 Versus Docetaxel in Previously Treated Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients

Primary Objectives: Study is designed with two primary endpoints that will be analyzed on randomized participants at the time of the cutoff date for each given analysis (progressive free survival [PFS] and overall survival [OS]). Study success is defined either on PFS or OS The primary objective is to determine …

platinum-based chemotherapy
measurable disease
cancer
docetaxel
squamous non-small cell lung cancer
Investigational Site Number 0320005
 (0.5 away) Contact site
  • 23 views
  • 18 Apr, 2021
  • +217 other locations
A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV) Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals

The purpose of this study is to evaluate the vaccine efficacy (VE) of a heterologous vaccine regimen utilizing Ad26.Mos4.HIV and aluminum phosphate-adjuvanted Clade C gp140 and Mosaic gp140 for the prevention of HIV-1 infection in HIV-1 seronegative cis-gender men and transgender individuals having sex with cis-gender men and/or transgender individuals.

Instituto Caici Srl.
 (2.6 away) Contact site
  • 74 views
  • 28 Jun, 2021
  • +78 other locations